Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded up 3.4% during trading on Tuesday . The stock traded as high as $11.30 and last traded at $11.06, with a volume of 546,986 shares. The stock had previously closed at $10.70.

Several research analysts have recently commented on the company. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, May 2nd. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a report on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 13th. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Finally, Leerink Swann reissued a “buy” rating and set a $12.00 price target on shares of Seres Therapeutics in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $31.57.

The firm’s 50-day moving average is $23.31 and its 200 day moving average is $26.53. The company’s market capitalization is $459.93 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.24. The firm earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. The firm’s revenue was up NaN% on a year-over-year basis. During the same period in the previous year, the business posted ($1.45) earnings per share. Equities analysts anticipate that Seres Therapeutics Inc. will post ($2.14) earnings per share for the current fiscal year.

In other news, insider Michele Trucksis sold 4,156 shares of the stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $35.18, for a total value of $146,208.08. Following the completion of the sale, the insider now directly owns 4,156 shares of the company’s stock, valued at $146,208.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Roger Pomerantz sold 9,801 shares of the stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $30.00, for a total value of $294,030.00. Following the completion of the sale, the chief executive officer now directly owns 193,493 shares of the company’s stock, valued at $5,804,790. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Morgan Stanley raised its stake in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 225.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,758 shares of the company’s stock after buying an additional 23,381 shares during the period. Morgan Stanley owned approximately 0.09% of Seres Therapeutics worth $1,185,000 at the end of the most recent reporting period.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.